Every Form 4 that Heartbeam, Inc. (BEAT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BEAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAT filings page.
HeartBeam, Inc. granted director Willem Elfrink 93,750 restricted stock units and options to buy 93,750 common shares on October 2, 2026. Each RSU represents a contingent right to one common share; the RSUs vest in full on the earlier of October 2, 2027 or the next annual meeting of stockholders following the grant date, subject to continued service. Half the options vest on the grant date and half on January 1, 2027, subject to continued service. The options have a $0.435 exercise price, expire October 2, 2036, and unvested options accelerate immediately before a Change in Control.
HeartBeam, Inc. director Richard Ferrari received two restricted stock unit awards on October 2, 2026: 125,000 annual RSUs and 90,625 special RSUs, plus an option covering 125,000 shares at an exercise price of $0.435 per share. The option was granted for his additional responsibilities as Chair of the Board; the reported post-grant position was 125,000 shares subject to the option, which expires October 2, 2036.
The annual RSUs vest in full on the earlier of October 2, 2027 or the issuer’s next annual meeting of stockholders after the grant, subject to continued service as a non-employee director. Half of the special RSUs vested on the grant date, with the rest scheduled to vest January 1, 2027 subject to continued service; unvested RSUs vest in full immediately before a Change in Control if service continues through that date. The option vests in monthly installments, subject to continued service, and will be fully vested on July 1, 2027.
HeartBeam, Inc. reported that director Michael R. Jaff received two restricted stock unit (RSU) awards on October 2, 2026: 93,750 RSUs as an annual non-employee director award and 37,500 RSUs as a special award connected to suspension of cash retainers from July 1 through December 31, 2026. Each RSU represents a contingent right to one common share upon vesting. The annual award vests on the earlier of October 2, 2027, or the next annual meeting, subject to continued service. Half of the special award vested on the grant date; the remainder vests January 1, 2027, subject to continued service. Unvested units under the special award vest in full immediately before a Change in Control, subject to continued service.
HeartBeam, Inc. director Marga Ortigas-Wedekind received 93,750 restricted stock units (RSUs) on October 2, 2026; each RSU represents a contingent right to one common share upon vesting. All RSUs vest on the earlier of October 2, 2027 or the next annual meeting after the grant, subject to continued service as a non-employee director. She also received options for 81,250 common shares at a $0.435 exercise price, expiring October 2, 2036. Half vest on the grant date and half on January 1, 2027, subject to continued service; any then-unvested shares fully accelerate immediately before a Change in Control.
HeartBeam, Inc.'s non-employee director Kenneth Warwick Nelson III was granted two direct restricted stock unit (RSU) awards on October 2, 2026: 93,750 RSUs as an annual award and 31,250 RSUs as a special award. Each RSU represents a contingent right to receive one share of common stock upon settlement.
The annual award vests in full on the earlier of October 2, 2027 or the next annual meeting after the grant, subject to continued service. The special award was granted in connection with suspended cash retainers for July 1 through December 31, 2026; half vested on the grant date and the remaining RSUs will vest January 1, 2027, subject to continued service. Unvested special-award RSUs vest in full immediately before a Change in Control, subject to continued service.
HeartBeam, Inc. (BEAT) non-employee director George de Urioste received 93,750 restricted stock units and a stock option covering 93,750 common shares on October 2, 2026. The option has a $0.435 per-share exercise price and expires October 2, 2036. The RSUs vest in full on the earlier of October 2, 2027 or the date of the next annual meeting following the grant date, subject to continued service as a non-employee director. Half of the option shares vest on the grant date and the remaining half on January 1, 2027, subject to continued service through the applicable vesting dates; any then-unvested shares accelerate immediately prior to a Change in Control, as defined in the Plan.
HeartBeam, Inc. reported that Chief Technology Officer Kenneth Harry Persen acquired 105,740 shares of common stock on July 24, 2026 through a grant treated as Restricted Stock Units under the 2022 Equity Incentive Plan.
The RSUs vested in full on the grant date as part of the 2025 Bonus Program, with executives receiving shares in lieu of cash. Following this award, Persen directly holds 448,290 shares of HeartBeam common stock.
Cruickshank Tim reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported that CFO Tim Cruickshank received a grant of 167,760 shares of common stock in the form of Restricted Stock Units on July 24, 2026 under the 2022 Equity Incentive Plan. The RSUs vested in full on the grant date as shares-in-lieu-of-cash for the 2025 Bonus Program, increasing his directly held shares to 239,990.
Vajdic Branislav reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported equity awards to President and director Branislav Vajdic under its 2022 Equity Incentive Plan. On June 15, 2026 he was granted 2,800,000 performance-based PRSUs that vest over three years upon achievement of milestones and continued service. On July 24, 2026 he received 260,870 RSUs, which vested in full on the grant date and settled his 2025 bonus in shares instead of cash.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. President Robert Paul Eno reported an open-market purchase of common stock. On April 16, 2026, he bought 12,500 shares at $0.80 per share, increasing his direct holdings to 36,742 shares.
The purchased shares were acquired in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. His reported holdings include 23,333 RSUs that have vested as referenced in a prior Form 4 filing.
HeartBeam, Inc. director Marga Ortigas-Wedekind purchased 25,000 shares of Common Stock on April 16, 2026 in an open-market transaction at $0.80 per share, bringing her direct holdings to 137,293 shares.
According to a footnote, these shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for this offering, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director-associated entities acquired 750,000 shares of common stock at $0.80 per share in an underwritten public offering of 12,500,000 shares. The purchase was an open-market style transaction tied to the offering that priced on April 14, 2026 and closed on April 16, 2026.
The shares are held by Strome Mezzanine Fund II, LP, the Mark E. Strome Living Trust and Strome Dynasty, LLC. Following this transaction, entities associated with director Mark E. Strome hold 3,650,000 shares of HeartBeam common stock indirectly. Mr. Strome has voting and disposal authority but disclaims beneficial ownership beyond his pecuniary interest.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.
HeartBeam, Inc. director Richard Ferrari reported an equity award of 50,000 shares of common stock in the form of restricted stock units. The grant was made on February 9, 2026 and increased his directly held position to 229,136 shares.
According to the award terms, one half of the RSU shares will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The RSUs were issued under HeartBeam’s 2022 Equity Incentive Plan and carry no cash exercise price.
HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.
HeartBeam, Inc. director receives equity award. Director Michael R. Jaff acquired 20,689 shares of HeartBeam common stock as a grant of restricted stock units (RSUs) at no cash cost on February 9, 2026. Following this award, he holds 95,809 shares directly.
The RSUs were granted under the company’s 2022 Equity Incentive Plan. One half of the shares subject to this special RSU grant are scheduled to vest on March 31, 2026, with the remaining half scheduled to vest on June 30, 2026, subject to the stated vesting terms.
HeartBeam, Inc. reported that President and director Branislav Vajdic received a grant of options to buy 61,932 shares of common stock at an exercise price of $1.45 per share. The options were granted on February 9, 2026 and expire on January 1, 2036.
According to the vesting terms, one half of the shares subject to this special option will vest on March 31, 2026, with the remaining shares vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. After this grant, Vajdic holds options for 61,932 underlying shares under the company’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported a routine equity compensation grant to its CFO, Tim Cruickshank. He received stock options covering 53,104 shares of common stock at an exercise price of $1.45 per share. Half of these options vest on March 31, 2026 and the remainder on June 30, 2026 under the 2022 Equity Incentive Plan.
HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.
According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.
Nelson Kenneth Warwick III reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. director Nelson Kenneth Warwick III reported a compensation grant of 17,241 restricted stock units (RSUs) of common stock. These RSUs were granted on February 9, 2026 at no cash cost and increase his direct holdings to 144,388 shares.
According to the grant terms, one half of the RSUs will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The award was issued under HeartBeam’s 2022 Equity Incentive Plan, highlighting routine equity-based director compensation rather than an open-market purchase.
HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.
According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.